Klinická farmakologie a farmacie – 2/2020

www.klinickafarmakologie.cz  / Klin Farmakol Farm 2020; 34(2): 47–55 / KLINICKÁ FARMAKOLOGIE A FARMACIE 55 HLAVNÍ TÉMA Terapeutické monitorování léčiv – review címúčinkům) a nastavení referenčních rozmezí je často teprve úkolem do budoucnosti. Závěr Terapeutické monitorování léčiv bývá ozna­ čováno jako „klíč“ personalizované farmakote­ rapie řady onemocnění. Jedná se o specifickou metodu oboru klinická farmakologie, jejímž základním předpokladem je existence užšího vztahu mezi farmakologickým účinkem léčiva a jeho koncentrací v organismu než s jeho dáv­ kou. Správně provedené TDM pomůže pomocí stanovení koncentrace léčiva v krvi následované erudovanou interpretací klinickým farmakolo­ gem (případně farmaceutem) a zpětnou vazbou s indikujícím klinikem nastavit optimální dávku léčiva u konkrétního pacienta, což umožní ra­ cionalizaci farmakoterapie s minimalizací rizika výskytu nežádoucích účinků, snížení mortality i morbidity, snížení nákladů na léčebnou péči a zejména zlepšení kvality života pacienta. LITERATURA 1. Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl ML. The­ rapeutic drug monitoring for tomorrow. Eur J Clin Pharma­ col 2013; 69(1): 25–32. 2. Grundmann M, Kacířová I. Význam TDM, fenotypizace a genotypizace pro správné dávkování léčiv. Čas Lék čes 2010; 149: 482–487. 3. Dave V, Yadav RB, Yadav S, Sharma S, Sahu RK, Ajayi AF. A cri­ tique of computer simulation software’s used in pharmacoki­ netics and pharmacodynamics analysis. Curr Clin Pharmacol 2018; 13(4): 216–235. 4. Kacířová I, Grundmann M. TDM antibiotik v klinické praxi. Kardiol Rev Int Med 2015; 17(1): 57–64. 5. Kacířová I, Grundmann M. Terapeutické monitorování ami­ kacinu a gentamicinu v rutinní klinické praxi. Vnitř Lék 2015; 61(1): 33–41. 6. Abdul‑Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicro­ bial therapeutic drug monitoring in critically ill adult patients: a Position Paper [published online ahead of print, 2020 May 7]. Intensive Care Med 2020; 1–27. 7. Suchánková H, Matušková Z, Vanduchová A. Terapeutické monitorování beta‑laktamových antibiotik. Klin mikrobiol inf lék 2017; 23(1): 4–9. 8. Ben Romdhane H, Ben Fredj N, Chaabane A, et al. Inte­ rest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen. Nephrol Ther 2019; 15(2): 110–114. 9. Young DC, Zobell JT, Stockmann C, et al. Optimization of anti‑pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations:V. Aminoglycosides. Pediatr Pulmonol 2013; 48: 1047–1061. 10. Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J 2011; 41(6): 441–449. 11. MooreRD,LietmanPS,SmithCR.Clinicalresponsetoamino­ glycosidetherapy: importanceoftheratioofpeakconcentration tominimal inhibitoryconcentration.J InfectDis1987;155:93–99. 12. Boyer A, Gruson D, Bouchet S, et al. Aminoglycosides in septic shock: an overview, with specific consideration gi­ ven to their nephrotoxic risk. Drug Saf 2013; 36(4): 217–230. 13. Alqahtani S, Alhumoud A, Abushomi H, Alsultan A, Bal­ khi B. Appropriate therapeutic drug monitoring of antibio­ tics contributed to lower nephrotoxicity. Int J Clin Pharma­ col Ther 2020 Feb; 58(2): 82–88. 14. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guide­ lines designed to achieve new target concentrations. J Anti­ microb Chemother 2009; 63(5): 1050–1057. 15. Moise‑Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicro­ bials in patients with Staphylococcus aureus lower respira­ tory tract infections. Clin Pharmacokinet 2004; 43: 925–942. 16. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommen­ dations from the infectious diseases Society of America, the American Society of Health‑System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49(3): 325–327. 17. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guide­ lines by the Infectious Diseases Society of America for the treatment of methicillin‑resistant Staphylococcus aureus in­ fections in adults and children: Executive summary. Clin In­ fect Dis 2011; 52(3): 285–292. 18. Helgason KO, Thomson AH, Ferguson C. A review of van­ comycin therapeutic drug monitoring recommendations in Scotland. J Antimicrob Chemother 2008; 61(6): 1398–1399. 19. Abdul‑Aziz MH, Lipman J, Roberts JA. Identifying „at‑risk“ patients for sub‑optimal beta‑lactam exposure in critically ill patients with severe infections. Crit Care 2017; 21: 21(1): 283. 20. Roberts JA, Paul SK, Akova M, et al. DALI: Defining Anti­ biotic Levels in Intensive Care Unit Patients: Are Current β­ ‑Lactam Antibiotic Doses Sufficient for Critically Ill Patients? Clin Infect Dis 2014; 58(8): 1072–1083. 21. Delattre IK, Taccone FS, Jacobs F, et al. Optimizing β­ ‑lactams treatment in critically‑ill patients using pharmacoki­ netics/pharmacodynamics targets: are first conventional do­ ses effective? Expert Rev Anti Infect Ther 2017; 15(7): 677–688. 22. Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Mo­ nitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit 2018; 40(5): 526–548. 23. Grundmann M, Kacířová I. Terapeutické monitorování hladin antiepileptik I. – obecné zásady, „stará“ antiepilepti­ ka. Klin Farmakol Farm 2016; 30(2): 9–15. 24. Kacířová I, Grundmann M. Terapeutické monitorování hla­ din antiepileptik II. - „nová“ antiepileptika, speciální skupiny pacientů. Klin Farmakol Farm 2016; 30(2): 16–22. 25. Reimers A, Berg JA, Burns ML, Brodtkorb E, Johannessen SI, Johannessen Landmark C. Reference ranges for antiepi­ leptic drugs revisited: a practical approach to establish na­ tional guidelines. Drug Des Devel Ther 2018; 12: 271–280. 26. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsy­ chopharmacology: Update 2017. Pharmacopsychiatry 2018; 51(1–02): 9–62. 27. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–533. 28. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871–878. 29. Ahmed A, Waagstein F, Pitt B, et al. Effectiveness of di­ goxin in reducing one‑year mortality in chronic heart fai­ lure in the Digitalis Investigation Group trial. Am J Cardiol 2009; 103(1): 82–87. 30. Grundmann M, Kacířová I. Personalizovaná farmakotera­ pie digoxinem. Vnitř Lék 2015; 61(5): 406–409. 31. Lopes RD, Rordorf R, De Ferrari GM, et al; ARISTOTLE Committees and Investigators. Digoxin and Mortality in Patients With Atrial Fibrillation. J Am Coll Cardiol 2018; 13; 71(10): 1063–1074. 32. Moffett BS, Garner A, Zapata T, Orcutt J, Niu M, Lopez KN. Serum digoxin concentrations and clinical signs and symp­ toms of digoxin toxicity in the paediatric population. Cardiol Young 2016; 26: 498–493. 33. Park M. Congestive heart failure. In: Park MK, (ed) Pedi­ atric Cardiology for Practitioners, (4 th ed) St Louis: Mosby; 2002: 403–406. 34. Gabarin N, Jaeggi ET, Spears DA, Sermer M, Silversides CK, Bhagra CJ. Concurrent maternal and fetal tachyarrhythmia in pregnancy. Obstet Med 2017; 10(4): 195–197. 35. Grundmann M, Koristkova B, Brozmanova H, Kaciro­ va I, Komzakova I. The interaction between digoxin and amiodarone during routine TDM. Ther Drug Monit 2005; 27(2): 219–220. 36. Hrudikova Vyskocilova E, Grundmann M, Duricova J, Kaci­ rova I. Therapeutic monitoring of amiodarone: pharmacoki­ netics and evaluation of the relationship between effect and dose/concentration. Biomed Pap Med Fac Univ Palacky Olo­ mouc Czech Repub 2017 Jun; 161(2): 134–143. 37. Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifun­ gal drugs: practical implications for optimized treatment of patients. Infection 2017 Dec; 45(6): 737–779. 38. Stott KE, Hope WW. Therapeutic drug monitoring for in­ vasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. J Antimicrob Chemo­ ther 2017; 72: i12–i18. 39. Ullmann AJ, Aguado JM, Arikan‑Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summa­ ry of the 2017 ESCMID‑ECMM‑ERS guideline. Clin Microbiol Infect 2018 May; 24 Suppl 1: e1–e38. 40. Arendrup MC, Cuenca‑Estrella M, Lass‑Flörl C, Hope WW. European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST­ ‑AFST). EUCAST technical note on Aspergillus and ampho­ tericin B, itraconazole, and posaconazole. Clin Microbiol In­ fect 2012; 18: E248–250. 41. Yi WM, Schoeppler KE, Jaeger J, et al. Voriconazole and posaconazole therapeutic drug monitoring: a ret­ rospective study. Ann Clin Microbiol Antimicrob. 2017 Sep 11; 16(1): 60. 42. Shuker N, van Gelder T, Hesselink DA. Intra‑patient varia­ bility in tacrolimus exposure: Causes, consequences for cli­ nical management. Transplant Rev (Orlando) 2015; 29: 78–84. 43. Snanoudj R, Rabant M, Royal V, Pallet N, Noel LH, Le­ gendre C. Nephrotoxicite des inhibiteurs de la calcineurine: presentation, problemes diagnostiques et facteurs de ris­ ques (Nephrotoxicity of calcineurin inhibitors: presentation, diagnostic problems and risk factors). Nephrol Ther 2009; 5(Suppl 6): S365–370. 44. del Mar Fernandez De Gatta M, Santos‑Buelga D, Dominguez‑Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic conside­ rations. Clin Pharmacokinet 2002; 41(2): 115–135. 45. Viklický O. Imunosuprese po transplantaci ledviny. Klinic­ ká farmakologie a farmacie. 2010; 24(2): 98–102. 46. Konsenzus IKEM; https://www2.ikem.cz/plm_lp/HVEZ­ DAADCG.htm; 6. 2. 2020. 47. Teřl M, Čáp P, Dvořáková R, et al. Doporučený postup dia­ gnostiky a léčby bronchiálního astmatu. Semily: GEUM; 2015. 48. http://www.sukl.cz/modules/medication/search.php; 4. 2. 2020. 49. Cooney L, Hawcutt D, Sinha I. The Evidence for Intrave­ nous Theophylline Levels between 10–20 mg/L in Children Suffering an Acute Exacerbation of Asthma: A Systematic Re­ view. PLoS One 2016 Apr 20; 11(4): e0153877.